Description In order to improve treatment of diabetes patients at home, the main goal of AP@Home is to build and evaluate an artificial pancreas (AP). The AP will allow automated glucose control: It monitors your blood glucose (sugar) levels and a software algorithm calculates how much insulin to deliver at any time via a built-in insulin infusion pump.Normally, insulin is given either by injections or via continuous infusion pumps. However, blood glucose levels can be greatly affected by many factors such as diet, physical activity, illness and stress so that it is difficult for patients to judge how much insulin they need.The automated artificial pancreas could not only improve the quality of life for people with insulin treated diabetes but also reduce the escalating healthcare cost burden.In the first phase of the AP@home project, the currently available AP algorithms were tested with monitoring systems and insulin pumps already on the market, using a “two-port” approach that requires two skin punctures to attach the glucose monitor and the insulin pump. In this stage, the aim was to improve the accuracy of the glucose sensors and the safety and effectiveness of the algorithms that relate insulin delivery to blood glucose levels.In parallel, innovative AP systems were developed that combine an insulin pump and a CGM system into a single device that uses only one access point through the skin. In the final year of the 4-year project, the performance of the newly created AP system, including remote monitoring facilities, will be compared with standard intensive insulin therapy in daily life in a multinational controlled trial.